Efficacy of Azacitidine in Transfusion-Dependent, ESA-Resistant Low/Int-1 Risk MDS

Overview

This phase II Nordic NMDSG08A study evaluated azacitidine (Aza) monotherapy and combination with ESA in 30 transfusion-dependent, ESA-resistant patients with low- and intermediate-1-risk myelodysplastic syndromes (MDS). The overall efficacy of Aza was limited, with considerable toxicity, and targeted sequencing revealed frequent mutations in splice factor genes and epigenetic regulators.

Background

Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders characterized by ineffective hematopoiesis and risk of progression to acute myeloid leukemia. Anemia predominates in low- and intermediate-1-risk MDS, with about 50% responding to erythropoiesis-stimulating agents (ESA). Patients refractory to growth factors require transfusions, which impair quality of life and may necessitate iron chelation. Azacitidine is approved for higher-risk MDS and has shown some efficacy in lower-risk patients, but its role in ESA-resistant, transfusion-dependent lower-risk MDS remains unclear.

Data Highlights

Key Findings

• Azacitidine monotherapy and combination with ESA showed limited overall efficacy in inducing transfusion independence in ESA-resistant, transfusion-dependent low/intermediate-1 risk MDS patients.
• Toxicity was considerable, including hematological toxicities requiring dose adjustments or treatment interruptions.
• Targeted gene sequencing revealed a high frequency of recurrent mutations, especially in spliceosome genes and epigenetic regulators.
• Previous studies suggested higher response rates in TET2-mutated patients and lower in ASXL1-mutated patients, but this study did not report definitive correlations.
• The study design included a primary endpoint of transfusion independence after six cycles of azacitidine, with addition of ESA for non-responders in subsequent cycles.

Clinical Implications

Azacitidine may have limited benefit in inducing transfusion independence in ESA-resistant, transfusion-dependent patients with lower-risk MDS, and treatment is associated with significant toxicity. Careful patient selection and monitoring for hematological adverse events are essential. Molecular profiling may help identify patients more likely to respond, but further studies are needed to clarify predictive biomarkers.

Conclusion

In this prospective phase II trial, azacitidine demonstrated limited efficacy and notable toxicity in ESA-resistant, transfusion-dependent low- and intermediate-1-risk MDS patients. The high prevalence of gene mutations underscores the heterogeneity of this population and the need for personalized therapeutic approaches.

References

1. Fenaux et al. 2009 -- Azacitidine prolongs survival in higher-risk MDS
2. Musto et al. -- Retrospective study on azacitidine in lower-risk MDS
3. Prebet et al. -- Azacitidine efficacy in lower-risk MDS
4. Santini et al. -- Prospective study of azacitidine in ESA-resistant lower-risk MDS
5. Bejar et al. 2011 -- Mutational landscape in lower-risk MDS